Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Crohn's Disease

Next Previous
Trial Profile

Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Crohn's Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Filgotinib (Primary)
  • Indications Crohn's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms Diversity1
  • Sponsors Galapagos NV; Gilead Sciences

Most Recent Events

  • 17 Oct 2023 Results assessing safety of FIL in Crohn's disease in DIVERSITY1 study and compared it with previously reported FIL safety data in ulcerative colitis from SELECTION study presented at the 31st United European Gastroenterology Week
  • 17 Oct 2023 Results of Efficacy and Safety of Filgotinib as Induction and Maintenance Therapy , presented at the 31st United European Gastroenterology Week
  • 03 Aug 2023 According to a Galapagos NV media release, based on the data from this study company decided not to submit a Marketing Authorization Application (MAA) in Europe for Crohn's disease (CD) and not to proceed with the MAA for filgotinib in UC in Switzerland.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top